Abstract:
High molecular weight buffering compositions and polymeric buffering compositions incorporating such compositions are described. The compositions are useful in applications where lower molecular weight buffers are unsatisfactory because of their tendency to leak out of an encapsulating membrane. Methods of making such compositions are described, as well as a particular application in a fiber optic carbon dioxide physiological probe.
Abstract:
There is disclosed a retortable plastic container (10) having a sidewall (11) and bottom wall (12) integrally formed as a single piece. The bottom wall has a heel portion (15) and a recessed center portion (16). The heel has a resting surface (14) and an inside corner (22). The recessed center portion has an outside corner (20). The container has an outside surface. The container is made in accordance with equations relating to reforming pressure and low fill equilibrium pressure and may be fabricated utilizing a variety of manufacturing modes since the providing of acceptable container configurations is not based on relative wall thicknesses. The bottom configuration, independent of relative wall thickness, eliminates paneling and other problems normally associated with plastic containers when they are subjected to sterilization.
Abstract:
A drug infusion manifold (10) that includes a housing defining a plurality of spaced apart fluid chambers (26) have a closed first end portion (28) and an opposing second end portion (30). The second end portions of immediately adjacent chambers are in fluid communication through channels (32) extending therebetween. A plurality of spaced apart fluid inlets (34) are formed in the housing in fluid communication with a corresponding fluid chamber. A check valve means (36) is provided in each fluid chamber for directing drugs and/or solutions from the inlets into the chamber and precluding fluid from the chamber. An outlet (38) is formed in the housing in direct fluid communication with at least one of the chambers.
Abstract:
A tablet is prepared from a powdered mixture by compacting the powder to remove air therefrom and causing physical granulation therein to yield a compact material containing granules. The granules are liberated from the compacted material and compressed into a tablet which is then provided with a coating. The starting powder mixture contains at least one material selected from amino acids, keto acids and polypeptides. The resultant tablet may be used in the treatment of chronic renal failure.
Abstract:
A method of separating phosphorus from condensed skim milk and from whey protein involves exposing the respective starting material to alumina particle while the starting material has a pH in the range of about 6.0 to 6.5. The alumina particles may be conditioned prior to use by exposing the particles to a solution containing a sulfate moiety. Both batch and continuous methods are disclosed. The figure is a graph showing the effect of alumina treatment on the calcium to phosphorus ratio in condensed skim milk.
Abstract:
A method to determine the presence or amount of peroxidase or hydrogen peroxide employing a sulfonephthalein dye or a phthalein dye having a major absorbance peak in the visible region, preferably at a wavelength from between about 500 nanometers to about 700 nanometers, and which absorbance peak is subject to a degree of oxidative extinguishment without strong alkali treatment, is disclosed. The method is performed by forming a reaction system comprising such sulfonephthalein dye or phthalein dye, and a test sample containing an unknown amount of (i) peroxide, (ii) a peroxidase, (iii) a compound which is capable of being oxidized to generate hydrogen peroxide, or (iv) a catalyst which participates in such oxidation, wherein the hydrogen peroxide causes peroxidase-catalyzed extinguishment of the absorbance peak of such dye whereby the unknown amount under determination can be determined by monitoring such extinguishment.
Abstract:
A connecting system is provided with a connector adapted to be mounted to the end of a conduit for removably engaging a blunt cannula to establish fluid communication between the conduit and cannula. The connector has a housing which defines a passage for communicating with the conduit and which defines an opening to the passage. The housing also defines a generally frustoconical seating surface which decreases in diameter in the direction toward the opening. A generally fluid-impervious, resilient seal is retained within the housing passage against the seating surface. The seal defines a slit which can accommodate penetration by the blunt cannula and which can reseal upon withdrawal of the blunt cannula.
Abstract:
A process for the preparation of 2-chloro-4,5-difluorobenzoic acid and 2,4,5-trifluorobenzoic acid as well as synthetic intermediates useful in and prepared according thereto, comprising reacting a nitrobenzene having formula (II), wherein X is chloro or fluoro, with an appropriate carbanion to form a compound having formula (III) wherein one of Y and Z is chloro and the other is nitro, and R is a radical selected from the group consisting of -CCl3, -CH2NO2, -CH(NO2)R , -CH(CO2R )2, -CH(C(O)R )2, -CH(CN)CO2R , -CH(CO2R )COR and -COR where R is alkyl or arylalkyl and R is alkyl, aryl or arylalkyl and, where appearing more than once in such a radical, R and R may be the same or different at each occurrence.
Abstract translation:一种制备2-氯-4,5-二氟苯甲酸和2,4,5-三氟苯甲酸的方法,以及可用于和制备的合成中间体,包括使具有式(II)的硝基苯(其中X为 氯或氟,与适当的碳负离子形成具有式(III)的化合物,其中Y和Z之一是氯,另一个是硝基,R是选自-CCl 3,-CH 2 NO 2,-CH (NO 2)R 1,-CH(CO 2 R 1)2,-CH(C(O)R 2)2,-CH(CN)CO 2 R 1,-CH(CO 2 R 1) COR 2和-COR 2,其中R 1是烷基或芳基烷基,R 2是烷基,芳基或芳基烷基,并且在这样的基团中出现不止一次,R 1和R 2 >在每次出现时可能相同或不同。
Abstract:
Monoclonal antibodies which specifically bind to Hepatitis C Virus (HCV) E2/NS1 antigen. Also provided are hybridoma cell lines which secrete these monoclonal antibodies, methods for using these monoclonal antibodies, and assay kits for assays which contain these monoclonal antibodies.
Abstract:
The present invention provides a unique recombinant antigen representing the distinct NS5 antigenic region of the HCV genome which can be used as reagents for the detection of antibodies and antigen in body fluids from individuals exposed to hepatitis C virus (HCV). The present invention also provides an assay for detecting the presence of an antibody to an HCV antigen in a sample by contacting the sample with the recombinant antigen. Preferred assay formats include a screening assay, a confirmatory assay, a competition or neutralization assay and an immunodot assay.